4-(2-amino-ethoxy)-aniline | 72210-18-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(2-amino-ethoxy)-aniline
• 英文别名: 4-Amino-phenol-(β-amino-aethyl)-aether；4-(2-Amino-aethoxy)-anilin；4-(2-Aminoethoxy)aniline
• CAS: 72210-18-5
• 化学式: C₈H₁₂N₂O
• mdl: MFCD04225862
• 分子量: 152.196
• InChiKey: BDMVWJHOWDSYFF-UHFFFAOYSA-N

物化性质

• 沸点：
  313.3±22.0 °C(Predicted)
• 密度：
  1.119±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  61.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-amino-ethoxy)-aniline 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 triethylamine tris(hydrogen fluoride) 、 sodium t-butanolate 作用下， 以 乙醇 、 异丙醇 、 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD

  摘要：

  A multivalent approach focused on amine-based secondary binding groups was applied to the discovery of long-acting inhaled beta(2)-agonists. Addition of amine moieties to the neutral secondary binding group of an existing beta(2)-agonist series was found to provide improved in vivo efficacy, but also led to the formation of biologically active aldehyde metabolites which were viewed as a risk for the development of these compounds. Structural simplification of the scaffold and blocking the site of metabolism to prevent aldehyde formation afforded a potent series of dibasic beta(2)-agonists with improved duration of action relative to their monobasic analogs. Additional optimization led to the discovery of 29 (TD-4306), a potent and selective beta(2)-agonist with potential for once-daily dosing. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.04.095
• 作为产物：
  描述：

  1-(2-叠氮乙氧基)-4-硝基苯 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 生成 4-(2-amino-ethoxy)-aniline
  参考文献：
  名称：

  Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors

  摘要：

  We designed a series of anilino-indoylmaleimides based on structural elements from literature JAK3 inhibitors 3 and 4, and our lead 5. These new compounds were tested as inhibitors of JAKs 1, 2 and 3 and TYK2 for therapeutic intervention in rheumatoid arthritis (RA). Our requirements, based on current scientific rationale for optimum efficacy against RA with reduced side effects, was for potent, mixed JAK1 and 3 inhibition, and selectivity over JAK2. Our efforts yielded a potent JAK3 inhibitor 11d and its eutomer 11e. These compounds were highly selective for inhibition of JAK3 over JAK2 and TYK. The compounds displayed only modest JAK1 inhibition. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.001

文献信息

• [EN] PROBES FOR RAPID AND SPECIFIC DETECTION OF MYCOBACTERIA<br/>[FR] SONDES POUR LA DÉTECTION RAPIDE ET SPÉCIFIQUE DE MYCOBACTÉRIES
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2017027062A1

  公开（公告）日：2017-02-16

  The compositions of the present disclosure provide novel fluorogenic probes for use in the specific imaging and detection of mycobacteria species, and in particular β-lactam- antibiotic resistant. Specificity for mycobacteria is conferred on these probes by incorporating a moiety that specifically targets the unique trapping mechanism of the DprE1 found in in mycobacteria. Accordingly, only Mycobacteria species that express both a β- lactamase and DprE1 enable both the activation of the caged fluorescent probe, and the affixing of the released fluorescent probes to the bacteria cells through the functioning reduction-covalent binding mechanism. Advantageously, such a probe is able, at its most sensitive, to allow single mycobacterium detection.

  本公开的组成提供了新颖的生色团探针，用于特定地成像和检测分枝杆菌种类，尤其是对β-内酰胺类抗生素具有抗药性的种类。这些探针通过引入一种特定针对分枝杆菌中DprE1独特捕获机制的基团，从而实现对分枝杆菌的特异性。因此，只有表达β-内酰胺酶和DprE1的分枝杆菌种类才能激活笼状荧光探针，并通过功能性还原-共价结合机制将释放的荧光探针固定到细菌细胞上。这种探针的一个显著优点是，在其最敏感的情况下，能够实现单个分枝杆菌的检测。
• [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060113A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种具有公式（I）的新化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• Structural Biology-Inspired Discovery of Novel KRAS–PDEδ Inhibitors
  作者：Yan Jiang、Chunlin Zhuang、Long Chen、Junjie Lu、Guoqiang Dong、Zhenyuan Miao、Wannian Zhang、Jian Li、Chunquan Sheng

  DOI：10.1021/acs.jmedchem.7b01243

  日期：2017.11.22

  protein and its ligand. Herein, an unprecedented chiral binding pattern was observed for inhibitors of KRAS–PDEδ interactions. Virtual screening and X-ray crystallography studies revealed that two enantiomers of a racemic inhibitor could bind at different sites. Fragment-based drug design was used to identify highly potent PDEδ inhibitors that can be used as promising lead compounds for target validation

  结构生物学是研究蛋白质与其配体之间立体定向相互作用的有力工具。在本文中，观察到了空前的手性结合模式，可抑制KRAS-PDEδ相互作用。虚拟筛选和X射线晶体学研究表明，外消旋抑制剂的两个对映异构体可以在不同位置结合。基于片段的药物设计用于鉴定高效的PDEδ抑制剂，这些抑制剂可作为有前途的先导化合物用于靶标验证和抗肿瘤药物开发。
• [EN] PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060112A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及具有式（I）的新化合物，其能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗多种疾病。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• [EN] TYROSINE-SPECIFIC FUNCTIONALIZED INSULIN AND INSULIN ANALOGS<br/>[FR] INSULINE ET ANALOGUES D'INSULINE FONCTIONNALISÉS SPÉCIFIQUES DE LA TYROSINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2019182942A1

  公开（公告）日：2019-09-26

  The present invention relates to tyrosine-specific functionalized insulin analogs and processes of making such tyrosine-specific functionalized insulin analogs using R-3H-1,2,4-triazoline-3,5-(4H)diones (PTAD).

  本发明涉及酪氨酸特异性功能化胰岛素类似物及使用R-3H-1,2,4-三唑烷-3,5-(4H)二酮（PTAD）制备这种酪氨酸特异性功能化胰岛素类似物的方法。